tiprankstipranks
Trending News
More News >
PAVmed Inc (PAVM)
NASDAQ:PAVM
US Market
Advertisement

PAVmed (PAVM) Earnings Dates, Call Summary & Reports

Compare
596 Followers

Earnings Data

Report Date
Mar 31, 2026
Before Open (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
-0.18
Last Year’s EPS
0.13
Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 13, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call highlighted several significant achievements, including successful Medicare endorsement for EsoGuard, strong financial positioning for Lucid, and strategic partnerships for Veris. However, challenges remain in debt restructuring and stagnant EsoGuard revenue growth.
Company Guidance
During PAVmed's Third Quarter 2025 Business Update Conference Call, several key metrics and strategic updates were discussed, highlighting the company’s financial and operational progress. A primary focus was on Lucid, PAVmed's main asset, which reported EsoGuard revenue of $1.2 million for the quarter with over 2,800 tests conducted, aligning with its target range of 2,500 to 3,000 tests. The company also highlighted a successful Medicare contractor meeting in September, which is expected to lead to near-term Medicare coverage. Lucid raised nearly $27 million through an underwritten public offering, ensuring a financial runway through 2026. For Veris, the company launched the commercial phase of its partnership with OSU, targeting 1,000 patients in the first year, and plans to submit its implantable device for FDA approval in 2026. Financially, PAVmed reported a non-GAAP loss of $446,000 and maintained an average non-GAAP operating expense of approximately $4.4 million over the last four quarters. The company’s strategic initiatives include expanding Veris's offerings to other academic centers and advancing an endoscopic imaging technology, with a regulatory strategy indicating a 510(k) pathway.
Successful Medicare Contractor Meeting
The experts unanimously endorsed Medicare coverage for EsoGuard, marking a final step towards near-term Medicare coverage for the test.
Lucid's Strong Financial Position
Lucid Diagnostics raised just under $27 million in an underwritten public offering, providing a sufficient runway through 2026.
Veris Commercial Partnership with OSU
Launched the commercial phase of the strategic partnership with OSU, targeting 1,000 patients in the first year.
Advancement of Implantable Device
Development work for the Veris implantable device is progressing well, with FDA submission planned for 2026.
Endoscopic Imaging Technology Licensing
Finalizing a license agreement for an Endoscopic Imaging Technology with Duke University and UNC.

PAVmed (PAVM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

PAVM Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Mar 31, 2026
2025 (Q4)
-0.18 / -
0.132
Nov 13, 2025
2025 (Q3)
-0.17 / -0.29
6.437-104.51% (-6.73)
Aug 14, 2025
2025 (Q2)
-0.13 / -0.74
-1.1937.82% (+0.45)
May 15, 2025
2025 (Q1)
- / 0.34
-2.62112.98% (+2.96)
Mar 24, 2025
2024 (Q4)
-0.11 / 0.13
-1.98106.67% (+2.11)
Nov 14, 2024
2024 (Q3)
1.98 / 6.44
-2.069411.12% (+8.51)
Aug 13, 2024
2024 (Q2)
-1.45 / -1.19
-1.8134.25% (+0.62)
May 14, 2024
2024 (Q1)
-1.67 / -2.62
-2.456-6.68% (-0.16)
Mar 26, 2024
2023 (Q4)
-1.63 / -1.98
-2.97433.42% (+0.99)
Nov 14, 2023
2023 (Q3)
-1.77 / -2.07
-3.74944.81% (+1.68)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

PAVM Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 13, 2025
$0.39$0.35-10.26%
Aug 14, 2025
$0.46$0.460.00%
May 15, 2025
$0.73$0.63-13.70%
Mar 24, 2025
$0.81$0.80-1.23%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does PAVmed Inc (PAVM) report earnings?
PAVmed Inc (PAVM) is schdueled to report earning on Mar 31, 2026, Before Open (Confirmed).
    What is PAVmed Inc (PAVM) earnings time?
    PAVmed Inc (PAVM) earnings time is at Mar 31, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is PAVM EPS forecast?
          PAVM EPS forecast for the fiscal quarter 2025 (Q4) is -0.18.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis